Bridgewater Associates LP Sells 83,807 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Bridgewater Associates LP lowered its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 73.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,533 shares of the life sciences company's stock after selling 83,807 shares during the period. Bridgewater Associates LP's holdings in Integra LifeSciences were worth $537,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD lifted its stake in shares of Integra LifeSciences by 6.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 35,421 shares of the life sciences company's stock worth $1,256,000 after acquiring an additional 2,114 shares during the period. Jane Street Group LLC lifted its holdings in shares of Integra LifeSciences by 181.1% in the first quarter. Jane Street Group LLC now owns 124,887 shares of the life sciences company's stock valued at $4,427,000 after purchasing an additional 80,463 shares in the last quarter. CWM LLC boosted its position in shares of Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock worth $37,000 after buying an additional 425 shares during the period. Olstein Capital Management L.P. lifted its position in shares of Integra LifeSciences by 13.0% in the second quarter. Olstein Capital Management L.P. now owns 113,000 shares of the life sciences company's stock worth $3,293,000 after purchasing an additional 13,000 shares in the last quarter. Finally, Cardinal Capital Management boosted its holdings in shares of Integra LifeSciences by 9.5% during the second quarter. Cardinal Capital Management now owns 34,034 shares of the life sciences company's stock worth $992,000 after purchasing an additional 2,965 shares during the period. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Price Performance

Integra LifeSciences stock traded up $0.05 during mid-day trading on Tuesday, hitting $24.63. 347,199 shares of the company were exchanged, compared to its average volume of 1,083,627. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $45.42. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The business has a fifty day moving average of $20.92 and a 200 day moving average of $23.94. The company has a market capitalization of $1.90 billion, a PE ratio of -271.19, a price-to-earnings-growth ratio of 0.84 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.02. The firm had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company's revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.76 earnings per share. As a group, sell-side analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on IART shares. Bank of America decreased their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a research note on Monday, October 7th. BTIG Research upgraded Integra LifeSciences from a "sell" rating to a "neutral" rating in a report on Monday, October 7th. Truist Financial lowered their price target on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, October 14th. Morgan Stanley started coverage on shares of Integra LifeSciences in a report on Monday. They set an "underweight" rating and a $20.00 price objective for the company. Finally, Citigroup upped their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a report on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences presently has an average rating of "Hold" and a consensus price target of $23.00.

Insider Transactions at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares of the company's stock, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 3.10% of the company's stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.